Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
Số trang: 10
Loại file: pdf
Dung lượng: 698.36 KB
Lượt xem: 8
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
To compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC). Sorafenib and sunitinib are both effective in treating mRCC. However, sorafenib might be more effective in elderly patients (≥65 years) and in patients with an ECOG status of 0, classified under MSKCC moderate risk.
Nội dung trích xuất từ tài liệu:
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
Nội dung trích xuất từ tài liệu:
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Metastatic renal cell carcinoma Overall survival Progressionfree survival Overall response rateGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 166 0 0 -
6 trang 165 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 138 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 106 0 0 -
12 trang 85 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 34 0 0
-
12 trang 33 0 0